Use of HLA-B∗58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: National prospective cohort study

BMJ (Online)

Volumn 351, Issue , 2015, Pages

  Ko, Tai Ming ^a,b   Tsai, Chang Youh ^c,d   Chen, Shih Yang ^e   Chen, Kuo Shu ^f   Yu, Kuang Hui ^g   Chu, Chih Sheng ^h,i,j   Huang, Chung Ming ^b,k   Wang, Chrong Reen ^l   Weng, Chia Tse ^l   Yu, Chia Li ^m   Hsieh, Song Chou ^m   Tsai, Jer Chia ^h,i,j   Lai, Wen Ter ^h,i,j   Tsai, Wen Chan ^h,i,j   Yin, Guang Dar ⁿ   Ou, Tsan Teng ^h,i,j   Cheng, Kai Hung ^h,i,j   Yen, Jeng Hsien ^h,i,j   Liou, Teh Ling ^c   Lin, Tsung Hsien ^h   Chen, Der Yuan ^d,o,p   Hsiao, Pi Jung ^h,i,j   Weng, Meng Yu ^l   Chen, Yi Ming ^d,o,p   Chen, Chen Hung ^q   Liu, Ming Fei ^l   Yen, Hsueh Wei ^h,i,j   Lee, Jia Jung ^h   Kuo, Mei Chuan ^r   Wu, Chen Ching ^h,i,j   Hung, Shih Yuan ^s,t   Luo, Shue Fen ^g,u   Yang, Ya Hui ^v,w   Chuang, Hui Ping ^a   Chou, Yi Chun ^a   Liao, Hung Ting ^a   Wang, Chia Wen ^a   Huang, Chun Lin ^a   Chang, Chia Shuo ^a   Lee, Ming Ta Michael ^a,x   Chen, Pei ^a   Wong, Chih Shung ^y,z   Chen, Chien Hsiun ^a,b   Wu, Jer Yuarn ^a,b   Chen, Yuan Tsong ^a,aa   Shen, Chen Yang ^a,k,ab   more..

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e Department of Surgery   (Taiwan)

^f TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^g CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^h KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^j KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^k CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^l NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^m NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

ⁿ Far Eastern Polyclinic   (Taiwan)

^o TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^p NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^q TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^r KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^s E DA HOSPITAL   (Taiwan)

^t I SHOU UNIVERSITY   (Taiwan)

^u CHANG GUNG UNIVERSITY   (Taiwan)

^v FOOYIN UNIVERSITY   (Taiwan)

^w KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^x RIKEN Center for Integrative Medical Sciences   (Japan)

^y CATHAY GENERAL HOSPITAL   (Taiwan)

^z PharmiGene   (Taiwan)

^aa DUKE UNIVERSITY MEDICAL CENTER   (United States)

^ab ACADEMIA SINICA   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; HLA B ANTIGEN; ANTIGOUT AGENT; HLA-B58 ANTIGEN;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; ADVERSE OUTCOME; AGED; ALLELE; ARTICLE; BLISTER; COHORT ANALYSIS; DISEASE SEVERITY; DNA PURIFICATION; DRUG INDICATION; EOSINOPHILIA; FATIGUE; FEMALE; FEVER; FOLLOW UP; GENOTYPE; GOUT; HLA B GENE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RISK ASSESSMENT; RISK FACTOR; SEVERE CUTANEOUS ADVERSE REACTION; SKIN DISEASE; SORE THROAT; STEVENS JOHNSON SYNDROME; SYMPTOM; TAIWAN; TAIWANESE; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; CHEMICALLY INDUCED; CHRONIC DISEASE; CLINICAL TRIAL; DRUG ERUPTIONS; GENETIC SCREENING; GENETICS; HETEROZYGOTE; MIDDLE AGED;

ALLOPURINOL; CHRONIC DISEASE; DRUG ERUPTIONS; EXANTHEMA; FEMALE; GENETIC TESTING; GENOTYPE; GOUT SUPPRESSANTS; HETEROZYGOTE; HLA-B ANTIGENS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PRURITUS; TAIWAN;

EID: 84947285140     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h4848     Document Type: Article

References (39)

1. Mini E, Nobili S. Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab 2009;6:17-24.
2. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-4.
3. Ng PC, Murray SS, Levy S, Venter JC. An agenda for personalized medicine. Nature 2009;461:724-6.
4. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002;8:5.
5. Greenberger PA. 8. Drug allergy. J Allergy Clin Immunol 2006;117:S464-70.
6. Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000;1:349-60.
7. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 2009;11:135-40.
8. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-51.
9. Neogi T. Clinical practice. Gout. N Engl J Med 2011;364:443-52.
10. Nuki G. An appraisal of the 2012 American College of Rheumatology guidelines for the management of gout. Curr Opin Rheumatol 2014;26:152-61.
11. Markel A. Allopurinol-induced DRESS syndrome. Isr Med Assoc J 2005;7:656-60.
12. Ramasamy SN, Korb-Wells CS, Kannangara DR, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf 2013;36:953-80.
13. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008;58:25-32.
14. ∗5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005;102:4134-9.
15. ∗58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol 2012;167:44-9.
16. ∗5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009;19:704-9.
17. Kang HR, Jee YK, Kim YS, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011;21:303-7.
18. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008;9:1617-22.
19. ∗58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics 2012;13:1193-201.
20. ∗58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. Br J Dermatol 2013;169:660-5.
21. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18:99-107.
22. Yun J, Mattsson J, Schnyder K, et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exp Allergy 2013;43:1246-55.
23. ∗58:01. J Immunol 2014;192:2984-93.
24. ∗58:01-restricted activation of drug-specific T cells and molecular interaction. J Allergy Clin Immunol 2015;135:1063-5.e5.
25. Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001;44:231-8.
26. Kim SC, Newcomb C, Margolis D, Roy J, Hennessy S. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis Care Res 2013;65:578-84.
27. Schneider G, Kachroo S, Jones N, et al. A systematic review of validated methods for identifying erythema multiforme major/minor/not otherwise specified, Stevens-Johnson Syndrome, or toxic epidermal necrolysis using administrative and claims data. Pharmacoepidemiol Drug Saf 2012;21 Suppl 1:236-9.
28. Lin HW, Tu Y Y, Lin SY, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 2011;12:900-4.
29. Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012;308:1906-14.
30. ∗1502 screening in Taiwan. N Engl J Med 2011;364:1126-33.
31. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007;7:317-23.
32. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 2013;93:153-8.
33. Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf 2008;31:643-65.
34. Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2014;73:328-35.
35. ∗5801 testing in preventing allopurinol-induced SJS/TEN in Thai population. PloS One 2014;9:e94294.
36. Park DJ, Kang JH, Lee JW, et al. Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea. Arthritis Care Res 2015;67:280-7.
37. ∗5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79.
38. Tohkin M, Kaniwa N, Saito Y, et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J 2013;13:60-9.
39. Chung WH, Chang WC, Stocker SL, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis 2014, doi:10.1136/annrheumdis-2014-205577.